Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 29;14(13):995.
doi: 10.3390/cells14130995.

Immunotherapy for Platinum-Resistant Ovarian Cancer as a Glimmer of Hope

Jan Brancewicz  1 , Irena Barbara Padzińska-Pruszyńska  2 , Małgorzata Kubiak  2 , Paulina Kucharzewska  2
Affiliations
Review

Immunotherapy for Platinum-Resistant Ovarian Cancer as a Glimmer of Hope

Jan Brancewicz et al. Cells. .

Abstract

Ovarian cancer is a leading cause of cancer-related deaths among women, with platinum resistance posing a significant challenge. Conventional therapies often fail in these cases, highlighting the urgent need for novel treatment approaches. Immunotherapy has emerged as a promising strategy, offering renewed hope for patients with platinum-resistant ovarian cancer (PROC). This review explores the current landscape of immunotherapies for PROC, discussing different approaches, their mechanisms of action, and the potential for overcoming the limitations of conventional treatments.

Keywords: cancer immunotherapy; cell-based therapies; ovarian cancer; tumor microenvironment; tumor-associated macrophages.

PubMed Disclaimer

Conflict of interest statement

Author Jan Brancewicz was employed by the company Cellis AG. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The company had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Factors driving the development of platinum resistance in OC cells. Created using BioRender.com.
Figure 2
Figure 2
Timeline of key milestones in the rise of OC immunotherapy.
Figure 3
Figure 3
Most promising immunotherapies for OC in development.
See this image and copyright information in PMC

References

    1. Webb P.M., Jordan S.J. Global Epidemiology of Epithelial Ovarian Cancer. Nat. Rev. Clin. Oncol. 2024;21:389–400. doi: 10.1038/s41571-024-00881-3. - DOI - PubMed
    1. Pejovic T., Fitch K., Mills G. Ovarian Cancer Recurrence: “Is the Definition of Platinum Resistance Modified by PARP Inhibitors and Other Intervening Treatments?”. Cancer Drug Resist. 2022;5:451–458. doi: 10.20517/cdr.2021.138. - DOI - PMC - PubMed
    1. Tung K.-H., Goodman M.T., Wu A.H., McDuffie K., Wilkens L.R., Nomura A.M.Y., Kolonel L.N. Aggregation of Ovarian Cancer with Breast, Ovarian, Colorectal, and Prostate Cancer in First-Degree Relatives. Am. J. Epidemiol. 2004;159:750–758. doi: 10.1093/aje/kwh103. - DOI - PubMed
    1. Hemminki K., Sundquist J., Brandt A. Incidence and Mortality in Epithelial Ovarian Cancer by Family History of Any Cancer. Cancer. 2011;117:3972–3980. doi: 10.1002/cncr.26016. - DOI - PubMed
    1. Kempf E., Desamericq G., Vieites B., Diaz-Padilla I., Calvo E., Estevez P., Garcia-Arreza A., Martinez-Maestre M.A., Duran I. Clinical and Pathologic Features of Patients with Non-Epithelial Ovarian Cancer: Retrospective Analysis of a Single Institution 15-Year Experience. Clin. Transl. Oncol. 2017;19:173–179. doi: 10.1007/s12094-016-1517-x. - DOI - PubMed

LinkOut - more resources